Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX
Sponsor: European Institute of Oncology
Summary
To prospectively evaluate the impact of HER2DX on the decision-making processes of the treating physicians and especially among the routine multidisciplinary tumour board, in defining type and setting of systemic therapy administration in patients with stage I-III HER2+ BC, and the degree of clinician's confidence in the treatment recommendation.
Official title: Prospective Observational Monocentric Study to Evaluate the Impact of the HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2-BREAST-DX
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2024-10-24
Completion Date
2027-11
Last Updated
2026-02-11
Healthy Volunteers
No
Interventions
Neoadjuvant standard treatment for HER2+
NEOADJUVANT SETTING
Adjuvant standard treatment for HER2+
ADJUVANT SETTING
Locations (1)
Istituto Europeo di Oncologia
Milan, Italy, Italy